NCT03291873

Brief Summary

This study will include patients who will undergo PRK in both eyes, for each patient each eye will be randomly allocated to one of 2 procedures: topography-guided ablation in one eye (group I) and Q-factor customized ablation in the other eye (group II). Alcon/Wavelight Light Laser Technolo¬gie (GmbH, Erlangen, Germany) will be used for photoablation. The wavelight Topolyzer (Wavelight AG, Erlan¬gen, Germany)and CSO Sirius scheimpflug camera combined with Placido corneal topography (CSO, Florence,Italy) will be used before and 1, 3 and 6 months after PRK. Refrac¬tive visual outcomes and corneal aberration changes will be compared between the two treatment modalities.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2017

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 8, 2017

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 25, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

October 25, 2017

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2019

Completed
Last Updated

July 7, 2020

Status Verified

July 1, 2020

Enrollment Period

1.7 years

First QC Date

August 8, 2017

Last Update Submit

July 1, 2020

Conditions

Outcome Measures

Primary Outcomes (7)

  • change in Postoperative spherical equivalent depending on manifest refraction after autorefractometer

    1 , 3 and 6 months postoperative

  • change in visual acuity using snellen chart

    1 , 3 and 6 months postoperative

  • change in corneal wavefront aberrations

    assessed by topolyzer

    1 , 3 and 6 months postoperative

  • change in Q value anterior at 6mm RMS, RMS of astigmatism, RMS of coma and RMS of spherical aberrations. Strehl ratio : Qvalue,RMS,strehl ratio by CSO Sirius scheimpflug

    by CSO Sirius scheimpflug

    1,3 and 6months

  • change in total RMS

    by CSO Sirius scheimpflug

    1,3 and 6months

  • change in strehl ratio

    by CSO scheimpflug

    1,3 and 6 months

  • change in Q value

    assessed by topolyzer

    1,3 and 6 months

Secondary Outcomes (5)

  • efficacy:ratio of postoperative decimal UDVA to preoperative decimal CDVA

    6 months

  • contrast sensitivity

    6 months

  • predictability

    6 months

  • safety:ratio of mean preoperative decimal CDVA to mean postoperative decimal CDVA

    6 months

  • stability

    6 months

Study Arms (2)

topography guided PRK in one eye

ACTIVE COMPARATOR

Topography-guided (placido disk- based) using T-CAT Contoura treatment.

Procedure: PRK

Q-value adjusted ( custom Q) PRK in the other eye

ACTIVE COMPARATOR

The target Q will be estimated according to a nomogram considering the patient's age

Procedure: PRK

Interventions

PRKPROCEDURE

PRK using Alcon-Wavelight Excimer Laser EX 500

Q-value adjusted ( custom Q) PRK in the other eyetopography guided PRK in one eye

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age more than 18 years
  • Myopia with up to -6.5 D with or without astigmatism up to -4.75 D

You may not qualify if:

  • anterior segment abnormalities (ie, cataracts, corneal scarring)
  • basement membrane disease
  • history of recurrent corneal erosions
  • Schirmer's test less than 5 mm
  • established or forme fruste keratoconus
  • macular or retinal disease
  • current use of immunosuppressive therapy
  • autoimmune disease
  • pregnancy, and lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Eyecare centre

Maadi, Cairo Governorate, Egypt

Location

Dar Al Oyun hospital

Giza, Egypt

Location

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisstant lecturer Faculty of Medicine Helwan University

Study Record Dates

First Submitted

August 8, 2017

First Posted

September 25, 2017

Study Start

October 25, 2017

Primary Completion

June 25, 2019

Study Completion

June 25, 2019

Last Updated

July 7, 2020

Record last verified: 2020-07

Locations